1 |
Gadola SD, Gross WL. Vasculitis in 2011: The renaissance of granulomatous inflammation in AAV[J]. Nat Rev Rheum, 2012,8:74-76.
|
2 |
Jennette JC, Falk RJ, Hu P, et al. Pathogenesis of antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis[J]. Annu Rev Pathol, 2013, 8: 139-160.
|
3 |
Lyons PA, Rayner TF, Trivedi S, et al. Genetically distinct subsets within ANCA-associated vasculitis[J]. N Engl J Med, 2012, 367: 214-223.
|
4 |
Martorana D, Maritati F, Malerba G, et al. PTPN22 R620W polymorphism in the ANCA-associated vasculitides[J]. Rheumatology,2012,51: 805-812.
|
5 |
Kondo T, Kawai T, Akira S. Dissecting negative regulation of Toll-like receptor signaling[J]. Trends Immunol, 2012,33:449-458.
|
6 |
Summers SA, Steinmetz OM, Gan PY, et al. Toll-like receptor 2 induces Th17 myeloperoxidase autoimmunity while Toll-like receptor 9 drives Th1 autoimmunity in murine vasculitis[J]. Arthritis Rheum,2011,63:1124-1135.
|
7 |
Broen JC, Bossini-Castillo L, van Bon L, et al. A rare polymorphism in the gene for Toll-like receptor 2 is associated with systemic sclerosis phenotype and increases the production of inflammatory mediators[J].Arthritis Rheum, 2012,64:264-271.
|
8 |
Netea MG, Wijmenga C, O'Neill LA. Genetic variation in Toll-like receptors and disease susceptibility[J]. Nat Immunol, 2012,13:535-542.
|
9 |
Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of wegener's granulomatosis[J].Arthritis Rheum, 1990,33:1101-1107.
|
10 |
Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of Systemic Vasculitides[J]. Arthritis Rheum, 1994,37:187-192.
|
11 |
Jayne D, Rasmussen N, Andrassy K, et al. A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies[J]. New Eng J Med, 2003,349:36-44.
|
12 |
Stegeman CA, Tervaert JW, Sluiter WJ, et al. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis[J]. Ann Intern Med, 1994,120:12-17.
|
13 |
Celhar T, Magalhaes R, Fairhurst AM. TLR7 and TLR9 in SLE: when sensing self goes wrong[J]. Immunol Res, 2012,53:58-77.
|
14 |
Uehara A, Sato T, Iwashiro A, et al. PR3-ANCA in Wegener's granulomatosis prime human mononuclear cells for enhanced activation via TLRs and NOD1/2[J]. Diagn Pathol, 2009,4: 23-26.
|
15 |
Durrani O, Banahan K, Sheedy FJ, et al. TIRAP Ser180Leu polymorphism is associated with Behcet's disease[J]. Rheumatology (Oxford),2011,50:1760-1765.
|
16 |
Tao K, Fujii M, Tsukumo S, et al. Genetic variations of Toll-like receptor 9 predispose to systemic lupus erythematosus in Japanese population[J].Ann Rheum Dis, 2007,66:905-909.
|
17 |
Demirci FY, Manzi S, Ramsey-Goldman R, et al. Association study of Tolllike receptor 5 (TLR5) and Toll-like receptor 9 (TLR9) polymorphisms in systemic lupus erythematosus[J]. J Rheum, 2007,34:1708-1711.
|
18 |
Yang Z, Liang Y, Qin B, et al. TLR9 polymorphisms and systemic lupus erythematosus risk in Asians: a meta-analysis study[J]. Cytokine,2012,57:282-289.
|
19 |
Jaen O, Petit-Teixeira E, Kirsten H, et al. No evidence of major effects in several Toll-like receptor gene polymorphisms in rheumatoid arthritis[J].Arthritis Res Ther, 2009,11:1123-1124.
|
20 |
Lee YH, Bae SC, Kim JH, et al. Toll-like receptor polymorphisms and rheumatoid arthritis: a systematic review[J]. Rheum Int, 2013,1:23-24.
|
21 |
Chamary JV, Parmley JL, Hurst LD. Hearing silence: non-neutral evolution at synonymous sites in mammals[J]. Nat Rev Genet, 2006,7:98-108.
|